Latest News and Press Releases

— Oral presentation Tuesday, June 3, 2025 in Chicago — LOS ANGELES, April 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage...

FDA RMAT designation follows positive proof-of-concept U.S. clinical data from the NXC-201 NEXICART-2 clinical trial in relapsed/refractory AL AmyloidosisRMAT designation potentially streamlines the...

Successfully dosed 6 patients in safety run-in segment, now accelerating enrollmentPositive data from first four patients announced December 2024NXC-201 is the only one-time CAR-T therapy in...

All four patients treated with NXC-201 normalized their disease markers within 30 days of dosing, of which, two are already classified as complete responders (CR), and the remaining two are bone...

Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling clinical activity, rapid and deep...

75% (12/16) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 4 lines of prior therapy in updated Phase 1/2 data as of...

- Company management will provide an update on positive new developments regarding CAR-T NXC-201 in relapsed/refractory AL Amyloidosis. Following management’s formal remarks, there will be a...

75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy Data will be presented on Monday, December 9, 2024 at 4:00 PM PT LOS...

Now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already successfully completed Each of these two doses have produced complete...

Dr. Comenzo was the senior author of the landmark Andromeda trial results published in the New England Journal of Medicine in 2021, resulting in the first FDA-approved therapy for AL...